Literature DB >> 17086360

Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents.

Christina Richard1, Jonathan Yau, John P H Th'ng, Wilhelmina C M Duivenvoorden.   

Abstract

Numerous cancer patients fail standard chemotherapy or develop resistance to chemotherapy during the course of treatment. The purpose of this study is to elucidate the overall response of cells obtained from cancer patients and from normal individuals to chemotherapeutic agents. We analysed the chemosensitivity of cancer cells derived from bone marrow and from pleural effusions or ascites fluids from patients with different cancers. Chemosensitivity to doxorubicin, cisplatin and paclitaxel was determined using the MTT assay. We also determined the response of bone marrow mononuclear (BMMN) cells. There was a wide range of responses to chemotherapy drugs in samples from different individuals. This was observed in cells derived from bone marrow and from ascites or pleural fluids. Large variations were also observed among morphologically normal BMMN cells and metastatic cancer cells from chemo-naïve patients. Cancer cells can easily be collected from ascites or pleural fluids and reliably assayed for chemosensitivity. We describe here that inherent chemoresistance may be a reason for the lack of response to chemotherapy in some patients. We discuss the potential of using the determination of natural resistance to dictate the drugs to be employed for treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17086360     DOI: 10.1007/s10585-006-9034-x

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

1.  Chemosensitivity testing predicts survival in ovarian cancer.

Authors:  C G Taylor; J M Sargent; A W Elgie; C J Williamson; G M Lewandowicz; O Chappatte; J G Hill
Journal:  Eur J Gynaecol Oncol       Date:  2001       Impact factor: 0.196

2.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; W Schachenmayr; R Schönmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

3.  Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.

Authors:  H Maier-Lenz; B Hauns; B Haering; J Koetting; K Mross; C Unger; T Bauknecht; A du Bois; H G Meerpohl; N Hollaender; K Diergarten
Journal:  Semin Oncol       Date:  1997-12       Impact factor: 4.929

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.

Authors:  E Klumper; R Pieters; G J Kaspers; D R Huismans; A H Loonen; M M Rottier; E R van Wering; A van der Does-van den Berg; K Hählen; U Creutzig
Journal:  Leukemia       Date:  1995-11       Impact factor: 11.528

7.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

8.  Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.

Authors:  Iranzu González; Enrique J Andreu; Angel Panizo; Susana Inogés; Ana Fontalba; José Luis Fernández-Luna; Mirella Gaboli; Luis Sierrasesúmaga; Salvador Martín-Algarra; Javier Pardo; Felipe Prósper; Enrique de Alava
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

9.  The clinical relevance of chemosensitivity testing in ovarian cancer.

Authors:  C G Taylor; J M Sargent; A W Elgie; F D Reid; P A Alton; J G Hill
Journal:  Cancer Detect Prev       Date:  1998

10.  Chemosensitivity testing of small cell lung cancer using the MTT assay.

Authors:  B G Campling; J Pym; H M Baker; S P Cole; Y M Lam
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.